ENCell Co., Ltd.
- Biotech or pharma, therapeutic R&D
- CMO, CRO
ENCell is a public South Korean company developing next-generation MSC therapies. Its lead asset, EN001, is a differentiated MSC overcoming first-generation limitations. EN001 has shown safety and exploratory efficacy in 20+ patients with CMT and DMD.
ENCelll is also specializes in CDMO (Contract Development and Manufacturing Organization) services meeting the highest GMP standard for advanced biopharmaceuticals, including cell and gene therapies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}